Erin Devanney
Family · Nags Head, NCNPI 1154882165
Payments from drug & device makers
Across 203 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$620
- Regeneron Healthcare Solutions, Inc.$460
- Amgen$264
- E.r. Squibb & Sons, L.L.C.$213
- UCB, Inc.$190
- plus $591 from 8 others
What the payments were for
- Food & beverage$3,85294%
- Education$2656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,779 |
| Johnson & Johnson | 32 | $620 |
| Regeneron Healthcare Solutions, Inc. | 21 | $460 |
| Amgen | 11 | $264 |
| E.r. Squibb & Sons, L.L.C. | 11 | $213 |
| UCB, Inc. | 8 | $190 |
| Galderma Laboratories, L.p. | 10 | $183 |
| Lilly USA, LLC | 6 | $136 |
| Sanofi | 3 | $78 |
| Novartis | 4 | $66 |
| Pfizer | 3 | $50 |
| LEO Pharma Inc. | 2 | $38 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $22 |
| Incyte Corporation | 1 | $18 |
How this compares
$4,117 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 15 | $301,185 |
| Enbrel SureclickEtanercept | 14 | $119,426 |
| Taltz AutoinjectorIxekizumab | 12 | $81,657 |
| Dupixent PenDupilumab | 15 | $55,584 |
| Dupixent SyringeDupilumab | 13 | $48,646 |
| Clobetasol Propionate | 145 | $8,005 |
| Ketoconazole | 218 | $3,143 |
| Fluorouracil | 33 | $2,568 |
| Metronidazole | 36 | $1,890 |
| Azelaic Acid | 13 | $1,862 |
| Triamcinolone Acetonide | 97 | $1,586 |
| Tretinoin | 29 | $1,173 |
| ValacyclovirValacyclovir Hcl | 27 | $1,134 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 83 | $1,073 |
| Fluocinonide | 26 | $924 |
Paid to pharmacies, not to this prescriber.
Other family in Nags Head
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.